Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 5:34 PM
Ignite Modification Date:
2025-12-24 @ 5:34 PM
NCT ID:
NCT00625768
Brief Summary:
To determine the tolerability, safety, end-organ toxicity and maximum tolerated dose of AS1409 in single and repeated doses.
Detailed Description:
* To determine the tolerability, safety, end-organ toxicity and maximum tolerated dose (MTD) of AS1409 in single and repeated doses.
* To determine biological responses to AS1409, including interferon-γ and IP-10 circulating concentrations.
* To determine preliminary pharmacokinetics of AS1409.
* To determine the immunogenicity of AS1409
* To explore the anti-tumour activity of AS1409.
Study:
NCT00625768
Study Brief:
Protocol Section:
NCT00625768